Author

Alexander A. Kolykhalov

Emory UniversityORCID 0000-0002-3966-9540Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Alexander L. GreningeriD· 2 shared Michael G. NatchusiD· 2 shared Zachary M. SticheriD· 2 shared Amalia Anne CruziD· 1 shared Andres MeritsiD· 1 shared Andrew T. GewirtziD· 1 shared Bennett DavenportiD· 1 shared Carolin M. LieberiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

Alexander L. GreningerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

EIDD-3525 is a broad-spectrum antiviral against alphavirus infection that targets the nsP4 RNA-dependent RNA polymerase

Peiqi Yin, Shweta Choudhary, Sainan Wang, Bennett Davenport, Phong Truong, Zachary M. Sticher, Rebecca E. Krueger, Amalia Anne Cruz, McKenzie Smith, Alexander A. Kolykhalov, Dariia Vyshenska, Alexander L. Greninger, Shuli Mao, Michael G. Natchus, George R. Painter, , Thomas E. Morrison

This study identifies EIDD-3525 as a broad-spectrum antiviral against alphaviruses that inhibits RNA replication by targeting the nsP4 polymerase.

bioRxiv · Sep 28, 2026 · PreprintMicrobiology

Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection

Carolin M. Lieber, Hae‐Ji Kang, Elizabeth B. Sobolik, Zachary M. Sticher, Vu L. Ngo, Andrew T. Gewirtz, Alexander A. Kolykhalov, Michael G. Natchus, Alexander L. Greninger, Mehul S. Suthar, Richard Karl Plemper

This study evaluates late-onset antiviral treatment in immunocompromised mice with persistent SARS-CoV-2 infection, finding that 4-FlU significantly reduces virus load, while paxlovid causes viral rebound.

Journal of Virology · Aug 29, 2024Peer-reviewedMicrobiology